Is ResMed (RMD) Worth More Than Its Cash Flow Suggests?

ResMed has delivered a powerful 68.9% gain over the past three years, which puts a spotlight on whether the current US$230.05 share price lines up with the cash the business can generate over time. With shorter term returns more mixed, the key issue now is how that recent share price history stacks up against what its cash flows suggest the stock might be worth.

• The 68.9% rise over three years means long term holders now have much more value tied to the question of how resilient and predictable ResMed's future cash flows really are.
• ResMed's focus on treating sleep and respiratory conditions can support recurring demand, which may influence how steadily it converts revenue into cash and how much flexibility it has to reinvest or return capital.
• If you'd rather focus on earnings, this one's for you. See what ResMed's 21.2x P/E says about the price.

The issue now is whether that recent share price, after a mixed run that includes a 14.5% decline over the past year and a 6.0% fall year to date, is justified by the intrinsic value suggested by its cash flows.

If you are weighing ResMed against similar opportunities that also hinge on cash generation strength, it can help to compare it with a broader set of companies in the solid balance sheet and fundamentals stocks screener (25 results).

Is ResMed Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model values ResMed by projecting the cash it could return to shareholders and then discounting those amounts back to today. In this view, the business is being assessed on the durability of its cash engine rather than headline earnings.

ResMed generated trailing twelve month free cash flow of about $1.66b, which gives the DCF a sizeable base to work from rather than a story that relies only on distant forecasts. Analysts and internal estimates used in this model point to growing free cash flow over the next decade, followed by a slower phase of expansion as the company matures. Based on those inputs, the DCF projections put ResMed's estimated intrinsic value substantially above the current share price of $230.05, so the current market quote implies a material discount to the cash flows embedded in this model. Find out what ResMed could be worth using our Discounted Cash Flow (DCF) estimate.

The ResMed Narrative: What Would Justify Today's Price?

ResMed's valuation puzzle only really comes into focus once you spell out the specific futures that could justify very different prices. Simply Wall St Narratives do that by linking each possible outcome to a clear view on how growth, profitability and risk might evolve, and by tying every number to an explicit path for margins and earnings that you can revisit as fresh information arrives on the Community page.

ResMed now splits the community, with one camp leaning into connected care upside while the other stresses execution risks and GLP 1 uncertainty.

Bull case: 7% undervalued

"Growth in ResMed’s connected device and digital health ecosystem, including AirSense 11, AirView, myAir and the GenAI coach Dawn, is improving therapy adherence and resupply behavior..."

Discover why this Narrative puts ResMed at 7% undervalued.

Bear case: 31% overvalued

"GLP-1 therapies are being framed internally as a once-in-a-generation demand opportunity. However, if broader weight loss adoption or new clinical data leads to fewer patients requiring CPAP, growth in device and mask revenue could fall short of current expectations..."

Explore why this Narrative puts ResMed at 31% overvalued.

For ResMed, the share price is only part of the story

Before you lean too heavily on cash flow models, it helps to know who is steering ResMed and how their pay packets line up with your interests. See who runs ResMed and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com